Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
about
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyAlternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem CellsLipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein.High expression of Mcl-1L via the MEK-ERK-phospho-STAT3 (Ser727) pathway protects melanocytes and melanoma from UVB-induced apoptosis.Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.Melanoma-derived IL-1 converts vascular endothelium to a proinflammatory and procoagulatory phenotype via NFκB activation.MicroRNAs in melanoma development and resistance to target therapy.Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.miR-193b and miR-30c-1 inhibit, whereas miR-576-5p enhances melanoma cell invasionBH3 mimetics induce apoptosis independent of DRP-1 in melanoma
P2860
Q26783032-5DD2E8A0-8283-4140-BBDB-A214CB1B3E54Q28084243-360CEF9C-9DDE-429F-B3D2-83FEDC8DCE1BQ35750142-BB47B0BF-82AB-4A67-9291-84CDAE72C843Q36192675-23F6E6BB-2098-40B7-91F4-A014B8F87FA1Q36562077-4E41E9B0-49DE-4E83-940D-6841A4CC1CF5Q36739519-8C7C4705-E389-4B93-B983-DEA4C287DE79Q38418019-BA5223BA-EF05-4EE2-97B7-B72462698BD4Q38943508-EF55BEE4-C833-4B5D-8B4B-18A9B7959C86Q38947009-CD075AED-5F0B-4522-92F2-82B717BFF46DQ38973890-D2361B18-DE1D-4F0C-A2AD-C27430C41883Q39101272-07C6E99C-6F0A-46C4-9BC3-C63C37FA07ADQ41470758-EF382BB5-5046-4C14-850A-99F58EFFDE09Q57168333-167CAAA6-D6CA-4FE3-BBBC-DE34F621E334Q58763373-CB8CB8BE-2DE9-40A8-AA4F-F01FD6D7A2B8
P2860
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
@en
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
@nl
type
label
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
@en
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
@nl
prefLabel
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
@en
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
@nl
P2093
P2860
P356
P1476
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma
@en
P2093
Christopher S McKee
David S Hill
Penny E Lovat
P2860
P304
P356
10.1111/EXD.12254
P577
2013-11-01T00:00:00Z